抗血小板药物基因检测在缺血性脑血管病二级预防中的作用  

The role of Antiplatelet drug gene detection in secondary prevention of ischemic cerebrovascular disease

作　　者：梁朝莹[1] 覃祖业[1] 黄翠艳[1] 李松良 农珍儒 LIANG Chaoying;QIN Zuye;HUANG Cuiyan;LI Songliang;NONG Zhenru(Department of Neurology,The First People’s Hospital of Qinzhou,Qinzhou,Guangxi 535000,China)

机构地区：[1]钦州市第一人民医院神经内科一区,广西钦州535000

出　　处：《医药前沿》2022年第21期36-38,42,共4页Journal of Frontiers of Medicine

基　　金：广西壮族自治区卫生健康委员会自筹经费科研课题《广西北部湾地区ABCB1、CYP2C19基因多态性与脑梗死预后相关性研究》(Z20190112)。

摘　　要：抗血小板药物是缺血性脑血管病二级预防的重要基石,其中氯吡格雷、阿司匹林是临床常用的治疗药物。个体的遗传差异是出现药物代谢酶、转运体和作用靶点等药物反应相关蛋白活性差异的原因之一,直接影响了药物的疗效和毒副作用。所以,正确地选择合适的抗血小板药物是避免急性脑血管病复发的关键因素。本文就抗血小板药物基因多态性在缺血性脑血管病二级预防中的作用进行综述。Anti-platelet is the important measure of clinical treatment and secondary prevention of ischemic cerebrovascular disease.Clopiologrel and Aspirin are the commonly used therapy.However,genetic factors that lead to drug metabolizing enzymes,transporters and targets of drug response associated protein for activity individual differences,thus affecting the clinical drug efficacy and toxicity.So,correct selection of appropriate anti-platelet drugs is the key factor to avoid acute stroke.In this review,we analyze the role of Antiplatelet drug gene detection in secondary prevention of ischemic cerebrovascular disease.

关 键 词：综述 缺血性脑血管病 基因检测 多态现象 遗传 

分 类 号：R543[医药卫生—心血管疾病]